Meperidine

DB00454

small molecule approved

Deskripsi

A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.

Struktur Molekul 2D

Berat 247.3327
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) = 3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.
Volume Distribusi Meperidine crosses the placenta and is distributed into breast milk.
Klirens (Clearance) -

Absorpsi

The oral bioavailability of meperidine in patients with normal hepatic function is 50-60% due to extensive first-pass metabolism. Bioavailability increases to 80-90% in patients with hepatic impairment (e.g. liver cirrhosis). Meperidine is less than half as effective when administered orally compared to parenteral administration. One study reported that 80-85% of the drug administered intramuscularly was absorbed within 6 hours of intragluteal injection in health adults; however, inter-individual variation and patient-specific variable appear to cause considerable variations in absorption upon IM injection.

Metabolisme

Meperidine is metabolized in the liver by hydrolysis to meperidinic acid followed by partial conjugation with glucuronic acid. Meperidine also undergoes N-demethylation to normeperidine, which then undergoes hydrolysis and partial conjugation. Normeperidine is about half as potent as meperidine, but it has twice the CNS stimulation effects.

Rute Eliminasi

Excreted in the urine. The proportion of drug that is excreted unchanged or as metabolites is dependent on pH. When urine pH is uncontrolled, 5-30% of the meperidine dose is excreted as normeperidine and approximately 5% is excreted unchanged. Meperidine and normeperidine are found in acidic urine, while the free and conjugated forms of meperidinic and normperidinic acids are found in alkaline urine.

Interaksi Makanan

2 Data
  • 1. Avoid alcohol.
  • 2. Take with or without food. Food does not significantly affect absorption.

Interaksi Obat

1820 Data
Buprenorphine Meperidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Meperidine.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Meperidine.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Meperidine.
Hydrocodone Meperidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Magnesium sulfate The therapeutic efficacy of Meperidine can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Meperidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Meperidine may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Meperidine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Meperidine.
Orphenadrine Meperidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Meperidine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Meperidine.
Pramipexole Meperidine may increase the sedative activities of Pramipexole.
Ropinirole Meperidine may increase the sedative activities of Ropinirole.
Rotigotine Meperidine may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Meperidine.
Sodium oxybate Meperidine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Meperidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Meperidine.
Thalidomide Meperidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Meperidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Alvimopan The risk or severity of adverse effects can be increased when Meperidine is combined with Alvimopan.
Desmopressin The risk or severity of hyponatremia can be increased when Meperidine is combined with Desmopressin.
Naltrexone The therapeutic efficacy of Meperidine can be decreased when used in combination with Naltrexone.
Levorphanol The risk or severity of adverse effects can be increased when Meperidine is combined with Levorphanol.
Remifentanil The risk or severity of adverse effects can be increased when Meperidine is combined with Remifentanil.
Diphenoxylate The risk or severity of adverse effects can be increased when Meperidine is combined with Diphenoxylate.
Dezocine The risk or severity of adverse effects can be increased when Meperidine is combined with Dezocine.
Methadyl acetate The risk or severity of adverse effects can be increased when Meperidine is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of adverse effects can be increased when Meperidine is combined with Dihydroetorphine.
Diamorphine The risk or severity of adverse effects can be increased when Meperidine is combined with Diamorphine.
Bezitramide The risk or severity of adverse effects can be increased when Meperidine is combined with Bezitramide.
Etorphine The risk or severity of adverse effects can be increased when Meperidine is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Meperidine is combined with Dextromoramide.
Desomorphine The risk or severity of adverse effects can be increased when Meperidine is combined with Desomorphine.
Carfentanil The risk or severity of adverse effects can be increased when Meperidine is combined with Carfentanil.
Alphacetylmethadol The risk or severity of adverse effects can be increased when Meperidine is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of adverse effects can be increased when Meperidine is combined with Dihydromorphine.
DPDPE The risk or severity of adverse effects can be increased when Meperidine is combined with DPDPE.
Lofentanil The risk or severity of adverse effects can be increased when Meperidine is combined with Lofentanil.
Normethadone The risk or severity of adverse effects can be increased when Meperidine is combined with Normethadone.
Piritramide The risk or severity of adverse effects can be increased when Meperidine is combined with Piritramide.
Alphaprodine The risk or severity of adverse effects can be increased when Meperidine is combined with Alphaprodine.
Nicomorphine The risk or severity of adverse effects can be increased when Meperidine is combined with Nicomorphine.
Meptazinol The therapeutic efficacy of Meperidine can be decreased when used in combination with Meptazinol.
Phenoperidine The risk or severity of adverse effects can be increased when Meperidine is combined with Phenoperidine.
Phenazocine The risk or severity of adverse effects can be increased when Meperidine is combined with Phenazocine.
Tilidine The risk or severity of adverse effects can be increased when Meperidine is combined with Tilidine.
Carfentanil, C-11 The risk or severity of adverse effects can be increased when Meperidine is combined with Carfentanil, C-11.
Ethylmorphine The risk or severity of adverse effects can be increased when Meperidine is combined with Ethylmorphine.
Ketobemidone The risk or severity of adverse effects can be increased when Meperidine is combined with Ketobemidone.
Alfentanil The risk or severity of adverse effects can be increased when Meperidine is combined with Alfentanil.
Fentanyl The risk or severity of adverse effects can be increased when Meperidine is combined with Fentanyl.
Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Meperidine.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Meperidine is combined with Dextropropoxyphene.
Benzhydrocodone The risk or severity of adverse effects can be increased when Meperidine is combined with Benzhydrocodone.
Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Meperidine.
Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Meperidine.
Oxycodone The risk or severity of adverse effects can be increased when Meperidine is combined with Oxycodone.
Sufentanil The risk or severity of adverse effects can be increased when Meperidine is combined with Sufentanil.
Oxymorphone The risk or severity of adverse effects can be increased when Meperidine is combined with Oxymorphone.
Dihydrocodeine The risk or severity of adverse effects can be increased when Meperidine is combined with Dihydrocodeine.
Opium The risk or severity of adverse effects can be increased when Meperidine is combined with Opium.
Naloxegol The risk or severity of adverse effects can be increased when Meperidine is combined with Naloxegol.
Pegvisomant The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Meperidine.
Succinylcholine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Meperidine.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Meperidine.
Cimetidine The serum concentration of Meperidine can be increased when it is combined with Cimetidine.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Meperidine.
Phenytoin The serum concentration of Meperidine can be decreased when it is combined with Phenytoin.
Fosphenytoin The serum concentration of Meperidine can be decreased when it is combined with Fosphenytoin.
Memantine The risk or severity of adverse effects can be increased when Meperidine is combined with Memantine.
Dicoumarol The risk or severity of adverse effects can be increased when Meperidine is combined with Dicoumarol.
Phenindione The risk or severity of adverse effects can be increased when Meperidine is combined with Phenindione.
Coumarin The risk or severity of adverse effects can be increased when Meperidine is combined with Coumarin.
Tioclomarol The risk or severity of adverse effects can be increased when Meperidine is combined with Tioclomarol.
Ethyl biscoumacetate The risk or severity of adverse effects can be increased when Meperidine is combined with Ethyl biscoumacetate.
Diphenadione The risk or severity of adverse effects can be increased when Meperidine is combined with Diphenadione.
4-hydroxycoumarin The risk or severity of adverse effects can be increased when Meperidine is combined with 4-hydroxycoumarin.
Fluindione The risk or severity of adverse effects can be increased when Meperidine is combined with Fluindione.
Clorindione The risk or severity of adverse effects can be increased when Meperidine is combined with Clorindione.
(R)-warfarin The risk or severity of adverse effects can be increased when Meperidine is combined with (R)-warfarin.
(S)-Warfarin The risk or severity of adverse effects can be increased when Meperidine is combined with (S)-Warfarin.
Tedizolid phosphate The risk or severity of serotonin syndrome can be increased when Tedizolid phosphate is combined with Meperidine.
Butalbital Butalbital may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine.
Pentobarbital Pentobarbital may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine.
Secobarbital Secobarbital may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine.
Methohexital Methohexital may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine.
Thiopental Thiopental may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine.
Primidone Primidone may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine.
Methylphenobarbital Methylphenobarbital may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine.
Thiamylal Thiamylal may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine.
Phenobarbital Phenobarbital may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine.
Amobarbital Amobarbital may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine.
Hexobarbital Hexobarbital may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine.
Barbital Barbital may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine.
Barbexaclone Barbexaclone may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine.
Butabarbital Butabarbital may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine.
Mirtazapine Meperidine may increase the serotonergic activities of Mirtazapine.

Target Protein

Kappa-type opioid receptor OPRK1
Glutamate receptor ionotropic, NMDA 1 GRIN1
Glutamate receptor ionotropic, NMDA 2B GRIN2B
Glutamate receptor ionotropic, NMDA 2A GRIN2A
Glutamate receptor ionotropic, NMDA 2C GRIN2C
Glutamate receptor ionotropic, NMDA 2D GRIN2D
Muscarinic acetylcholine receptor CHRM1
Mu-type opioid receptor OPRM1
Sodium-dependent dopamine transporter SLC6A3
Sodium-dependent noradrenaline transporter SLC6A2
Sodium-dependent serotonin transporter SLC6A4
Liver carboxylesterase 1 CES1

Referensi & Sumber

Contoh Produk & Brand

Produk: 95 • International brands: 7
Produk
  • Demerol
    Injection, solution • 50 mg/1mL • Intramuscular; Intravenous; Subcutaneous • US • Approved
  • Demerol
    Injection, solution • 50 mg/1mL • Intramuscular; Intravenous; Subcutaneous • US • Approved
  • Demerol
    Injection, solution • 100 mg/1mL • Intramuscular; Intravenous; Subcutaneous • US • Approved
  • Demerol
    Injection, solution • 50 mg/1mL • Intramuscular; Intravenous; Subcutaneous • US • Approved
  • Demerol
    Injection, solution • 100 mg/1mL • Intramuscular; Intravenous; Subcutaneous • US • Approved
  • Demerol
    Tablet • 50 mg/1 • Oral • US • Approved
  • Demerol
    Tablet • 100 mg/1 • Oral • US • Approved
  • Demerol
    Tablet • 50 mg/1 • Oral • US • Approved
Menampilkan 8 dari 95 produk.
International Brands
  • Dolantin — sanofi-aventis
  • Dolcontral — mibe
  • Dolosal — Cristália
  • Dolsin — Biotika
  • Lydol — Sopharma
  • Mialgin — Zentiva
  • Petidin — Nycomed

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul